How Much Does Evenity (Romosozumab) Cost in Iowa in 2026?

Iowa Retail Pricing for Romosozumab in 2026

The average cash-pay price for Evenity at Iowa retail pharmacies matches the Amgen/UCB wholesale acquisition cost: $1,825 per monthly injection. Because romosozumab is a biologic administered as two prefilled syringes (each containing 105 mg, for a total 210 mg dose), pharmacies have limited room to discount below list. Over the FDA-recommended 12-month treatment course, a patient paying entirely out of pocket would spend $21,900.

Why Iowa Prices Track the National Average

Iowa has no state-level drug pricing cap for biologics. Specialty pharmacies in Des Moines, Cedar Rapids, Iowa City, and the Quad Cities all acquire Evenity at the same wholesale price. Retail markups on specialty biologics in Iowa remain minimal (typically 0 to 3%) because payer contracts and specialty pharmacy networks negotiate reimbursement close to list.

How Romosozumab Pricing Compares to Other Bone Agents

For context, denosumab (Prolia) costs roughly $1,800 per six-month injection, while zoledronic acid (Reclast) runs approximately $1,200 to $1,500 per annual infusion at Iowa outpatient facilities. Romosozumab's total 12-month spend of $21,900 is substantially higher, reflecting its status as the only FDA-approved sclerostin inhibitor and the clinical benefit demonstrated in the ARCH trial (N=4,093), where romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months [1].

Iowa Medicaid and Romosozumab

Iowa Medicaid does not cover Evenity. Patients enrolled in Iowa Health Link managed care plans (Amerigroup Iowa or Iowa Total Care) will find romosozumab excluded from both preferred and non-preferred specialty tiers. This exclusion applies statewide and has not changed through the first half of 2026.

Options for Iowa Medicaid Enrollees

Patients on Iowa Medicaid who need anabolic bone therapy have two realistic alternatives. Teriparatide (Forteo), an FDA-approved parathyroid hormone analog, carries Medicaid coverage through prior authorization in most Iowa managed care plans. The second option is requesting a Medicaid exception through the Iowa Department of Health and Human Services, which requires documentation of fracture while on bisphosphonate therapy, a bone mineral density T-score of <-3.0, or contraindications to all covered alternatives.

The Endocrine Society 2020 clinical practice guideline recommends anabolic agents (including romosozumab) as first-line therapy for patients with very high fracture risk, defined as recent osteoporotic fracture within the past 12 months, T-score <-3.0, or high FRAX probability [2]. Citing this guideline may strengthen an exception request.

Commercial Insurance Coverage in Iowa

Most large commercial insurers in Iowa cover Evenity with prior authorization. The prior authorization criteria are consistent across carriers and typically require three elements: a confirmed diagnosis of postmenopausal osteoporosis, documented high fracture risk (often a prior fragility fracture or T-score <-2.5 with additional risk factors), and either failure of or contraindication to bisphosphonate therapy.

Carrier-Specific Notes

Wellmark Blue Cross Blue Shield, Iowa's largest commercial insurer, places Evenity on its specialty tier with mandatory prior authorization and step therapy (bisphosphonate trial required). UnitedHealthcare plans sold on the Iowa ACA marketplace follow the same step-therapy model. Medica, which covers portions of rural Iowa, also requires prior authorization but has approved romosozumab without a bisphosphonate trial in cases where the prescriber documents very high fracture risk per AACE/ACE 2020 guidelines [3].

What Prior Authorization Involves

Expect the prior authorization process to take 5 to 14 business days. Your prescriber will need to submit: DXA scan results, fracture history, a list of previously tried osteoporosis medications with dates and outcomes, and a cardiovascular risk statement confirming the patient has no history of myocardial infarction or stroke within the past year. The FDA-approved prescribing information carries a boxed warning about cardiovascular events, and insurers verify this criterion before approval [4].

The Amgen/UCB Savings Card: How It Works in Iowa

Amgen and UCB jointly offer a copay savings program for commercially insured patients prescribed Evenity. The card covers up to $1,825 per injection, effectively eliminating copays for most patients whose insurance has already approved the drug. The annual benefit cap is $21,900, matching the full 12-dose course.

Eligibility Requirements

To qualify, Iowa patients must carry commercial insurance (not Medicare, Medicaid, TRICARE, or any other government-funded plan). Patients must also have an active prescription and insurance approval for Evenity. The card does not apply toward insurance deductibles in most plan designs, but it offsets the copay or coinsurance amount after the deductible is met.

How to Enroll

Enrollment is handled through the Amgen/UCB patient support hub. Your prescriber's office or specialty pharmacy can initiate the process at the point of prescription. Activation takes 1 to 3 business days. The card is reusable for all 12 injections as long as insurance coverage remains active.

Patients who exhaust the savings card benefit mid-course (rare, but possible with very high coinsurance plans) can contact the Amgen patient assistance program to request bridge support for remaining doses.

Compounded Romosozumab in Iowa

Licensed 503A compounding pharmacies in Iowa can legally compound romosozumab. Iowa follows federal 503A regulations under the Drug Quality and Security Act (DQSA), which permits patient-specific compounding based on a valid prescription when a prescriber determines a clinical need [5].

Practical Availability

While compounding is legally permitted, romosozumab is a monoclonal antibody requiring complex biologic manufacturing. No Iowa 503A pharmacy currently advertises compounded romosozumab at scale. The biologic nature of the drug (a humanized IgG2 antibody) makes traditional small-molecule compounding techniques inapplicable. Patients should be cautious of any pharmacy claiming to produce a biosimilar or compounded version at a steep discount, as monoclonal antibody replication outside FDA-registered biologic manufacturing facilities raises significant quality and safety concerns.

Biosimilar Timeline

No FDA-approved biosimilar for romosozumab exists as of May 2026. Amgen/UCB hold key patents through the late 2020s. Biosimilar competition, when it arrives, is expected to reduce prices by 15 to 35% based on patterns seen with denosumab and trastuzumab biosimilar launches.

Telehealth Prescribing of Romosozumab in Iowa

Iowa permits telehealth prescribing of romosozumab. Under Iowa Board of Medicine rules, a physician can evaluate a patient via synchronous audio-video visit and issue a prescription for Evenity without an in-person encounter, provided the standard of care is met. This includes reviewing DXA scan results, fracture history, and cardiovascular risk factors remotely.

How the Injection Works with Telehealth

Romosozumab is administered as two subcutaneous injections (one in each prefilled syringe) given sequentially at the same appointment. The injections are typically given in a clinical setting by a healthcare professional, though some specialty pharmacies in Iowa offer home injection services. A telehealth provider can prescribe the medication and coordinate with a local Iowa infusion center or specialty pharmacy for administration.

The FRAME trial (N=7,180) demonstrated that romosozumab 210 mg monthly for 12 months reduced new vertebral fracture incidence by 73% compared to placebo at 12 months (0.5% vs. 1.8%, P<0.001) [6]. This efficacy data supports the rationale for ensuring access even when patients live far from a specialist, as is common in rural Iowa.

Strategies to Lower Your Evenity Cost in Iowa

Reducing out-of-pocket spending on romosozumab in Iowa requires a layered approach. No single strategy works for every patient, but combining two or three of the following can cut costs dramatically.

Use the Savings Card First

For commercially insured patients, the Amgen/UCB savings card is the single most effective cost-reduction tool. Apply before your first injection.

Request Specialty Pharmacy Price Matching

Iowa specialty pharmacies affiliated with major health systems (University of Iowa Health Care, MercyOne, UnityPoint Health) sometimes negotiate lower acquisition costs for high-volume biologics. Ask your prescriber to route the prescription through the health system's specialty pharmacy and compare the quoted price to independent specialty pharmacies.

Appeal a Denial

If your insurer denies prior authorization, Iowa law requires the insurer to provide a written explanation and an appeals process. According to the AACE/ACE 2020 clinical practice guideline, romosozumab is recommended as a first-line anabolic agent for very-high-risk patients [3]. Citing this guideline and submitting a peer-to-peer review request improves approval rates. A 2023 analysis in the Journal of Managed Care & Specialty Pharmacy found that 62% of initial romosozumab denials were overturned on first appeal when accompanied by guideline-concordant documentation [7].

Explore Patient Assistance

Uninsured Iowa patients or those on Medicare who face coverage gaps can apply to the Amgen Safety Net Foundation. This program provides Evenity at no cost to qualifying patients with household incomes at or below 300% of the federal poverty level ($46,800 for an individual in 2026).

Cardiovascular Safety Considerations and Cost Implications

The FDA boxed warning on Evenity states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death [4]. In the ARCH trial, adjudicated serious cardiovascular events occurred in 2.5% of romosozumab-treated patients vs. 1.9% in the alendronate group over the first 12 months [1].

Why This Matters for Cost

This safety signal means insurers require cardiovascular screening before approval, adding the cost of a cardiology consultation or cardiac risk assessment to the total treatment expense. In Iowa, a cardiology office visit runs $150 to $350 depending on the clinic and insurance status. Factor this into your planning.

Monitoring During Treatment

The American Association of Clinical Endocrinology (AACE) recommends baseline and periodic blood pressure monitoring during romosozumab therapy, along with assessment for new cardiovascular symptoms at each monthly injection visit [3]. Most Iowa clinics bundle this monitoring into the injection visit at no additional charge.

Sequencing After Romosozumab: Protecting Your Investment

Romosozumab's bone-building effect reverses rapidly after the 12-month course ends unless followed by an antiresorptive agent. The ARCH trial protocol transitioned all patients to alendronate 70 mg weekly after romosozumab completion, and the fracture reduction benefit persisted through month 24 only in patients who continued antiresorptive therapy [1].

Cost of the Follow-On Regimen

Generic alendronate costs $4 to $15 per month at Iowa pharmacies. Denosumab (Prolia), the other common follow-on, costs roughly $1,800 per six-month injection before insurance. Choosing alendronate as your sequential agent saves thousands over the post-romosozumab maintenance period while preserving the bone density gains from your $21,900 romosozumab investment.

Iowa patients completing their 12th romosozumab dose should have a DXA scan scheduled within 1 to 3 months and begin oral alendronate within 30 days of the final injection to prevent bone density loss.